Live Breaking News & Updates on Calithera Biosciences
Stay updated with breaking news from Calithera biosciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com assumed coverage on shares of Calithera Biosciences (NASDAQ:CALA – Free Report) in a report published on Friday. The firm issued a hold rating on the biotechnology company’s stock. Calithera Biosciences Price Performance Shares of NASDAQ:CALA opened at $0.02 on Friday. Calithera Biosciences has a 12-month low of $0.02 and a 12-month high of $0.50. […] ....
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.
StockNews.com initiated coverage on shares of Calithera Biosciences (NASDAQ:CALA – Free Report) in a research report released on Friday. The brokerage issued a hold rating on the biotechnology company’s stock. Calithera Biosciences Price Performance Shares of NASDAQ:CALA opened at $0.02 on Friday. The firm has a 50 day moving average of $0.02 and a 200 […] ....
Analysts' New Coverage for May 24th (AEZS, AIRG, AWX, AZUL, BCLI, BLPH, BWMN, BZ, CALA, CAMP) wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.
StockNews.com began coverage on shares of Calithera Biosciences (NASDAQ:CALA – Free Report) in a research report released on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Calithera Biosciences Stock Performance Calithera Biosciences stock opened at $0.02 on Thursday. The stock has a 50-day moving average of $0.02 and a two-hundred […] ....